Mihael Hristos Polymeropoulos Buys 20,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 20,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Friday, May 16th. The shares were bought at an average cost of $4.22 per share, for a total transaction of $84,400.00. Following the transaction, the chief executive officer now directly owns 2,315,731 shares of the company’s stock, valued at $9,772,384.82. This represents a 0.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Wednesday, March 5th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The stock was bought at an average cost of $5.02 per share, with a total value of $50,200.00.
• On Friday, February 28th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The stock was bought at an average cost of $4.76 per share, with a total value of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average cost of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock traded up $0.15 during midday trading on Monday, hitting $4.31. 547,638 shares of the company traded hands, compared to its average volume of 722,826. The firm’s fifty day moving average price is $4.43 and its 200-day moving average price is $4.63. The stock has a market cap of $254.01 million, a price-to-earnings ratio of -13.47 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. Finally, StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating for the company.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quantinno Capital Management LP acquired a new position in Vanda Pharmaceuticals in the 4th quarter valued at approximately $48,000. Linden Thomas Advisory Services LLC bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $49,000. Nations Financial Group Inc. IA ADV acquired a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at about $67,000. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth about $69,000. Finally, Virtu Financial LLC acquired a new position in shares of Vanda Pharmaceuticals in the first quarter worth approximately $72,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.